Cargando…

Outcomes of the conservative management of the patients with endometrial intraepithelial neoplasia/endometrial cancer: Wait or treat!

BACKGROUND/AIM: The objective of the study was to evaluate the response, relapse, reproductive results and demographic features of the patients with endometrioid adenocancer (EAC) and endometrial intraepithelial neoplasia (EIN) who were treated with conservative treatment. This is the largest study...

Descripción completa

Detalles Bibliográficos
Autores principales: İŞÇİ BOSTANCI, Esra, DURMUŞ, Yasin, DURU ÇÖTELİ, A.Sinem, KAYIKÇIOĞLU, Fulya, BORAN, Nurettin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569776/
https://www.ncbi.nlm.nih.gov/pubmed/34013707
http://dx.doi.org/10.3906/sag-2012-207
_version_ 1784594709718499328
author İŞÇİ BOSTANCI, Esra
DURMUŞ, Yasin
DURU ÇÖTELİ, A.Sinem
KAYIKÇIOĞLU, Fulya
BORAN, Nurettin
author_facet İŞÇİ BOSTANCI, Esra
DURMUŞ, Yasin
DURU ÇÖTELİ, A.Sinem
KAYIKÇIOĞLU, Fulya
BORAN, Nurettin
author_sort İŞÇİ BOSTANCI, Esra
collection PubMed
description BACKGROUND/AIM: The objective of the study was to evaluate the response, relapse, reproductive results and demographic features of the patients with endometrioid adenocancer (EAC) and endometrial intraepithelial neoplasia (EIN) who were treated with conservative treatment. This is the largest study when we consider the single center studies in this field. MATERIALS AND METHODS: In the current retrospective study, 38 patients (6 EAC, 31 EIN, 1 synchronous tumors of ovary and endometrium) were recruited. They were treated with progesterone products for their fertility desire and comorbidity. Reproductive results, response rates, and recurrence rates were calculated and survival analyses were performed. RESULTS: Mean duration of the medical treatment was 10 months (range 2–60). Among the 32 patients with EIN, 28 (87.5%) had a response, 8 (25%) had a relapse and 4 (12.5%) had persistence. Among the 32 patients who expecting fertility, seven patients got pregnant (21.8%) with a total of five live births. The median follow-up was 40.5 months (range 3–180), and recurrence-free interval was 28.7 months (range 2–180). CONCLUSION: Fertility-sparing treatment of EAC and EIN is a feasible approach, and the eligible patients should be given a chance to get pregnant.
format Online
Article
Text
id pubmed-8569776
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Scientific and Technological Research Council of Turkey
record_format MEDLINE/PubMed
spelling pubmed-85697762021-11-17 Outcomes of the conservative management of the patients with endometrial intraepithelial neoplasia/endometrial cancer: Wait or treat! İŞÇİ BOSTANCI, Esra DURMUŞ, Yasin DURU ÇÖTELİ, A.Sinem KAYIKÇIOĞLU, Fulya BORAN, Nurettin Turk J Med Sci Article BACKGROUND/AIM: The objective of the study was to evaluate the response, relapse, reproductive results and demographic features of the patients with endometrioid adenocancer (EAC) and endometrial intraepithelial neoplasia (EIN) who were treated with conservative treatment. This is the largest study when we consider the single center studies in this field. MATERIALS AND METHODS: In the current retrospective study, 38 patients (6 EAC, 31 EIN, 1 synchronous tumors of ovary and endometrium) were recruited. They were treated with progesterone products for their fertility desire and comorbidity. Reproductive results, response rates, and recurrence rates were calculated and survival analyses were performed. RESULTS: Mean duration of the medical treatment was 10 months (range 2–60). Among the 32 patients with EIN, 28 (87.5%) had a response, 8 (25%) had a relapse and 4 (12.5%) had persistence. Among the 32 patients who expecting fertility, seven patients got pregnant (21.8%) with a total of five live births. The median follow-up was 40.5 months (range 3–180), and recurrence-free interval was 28.7 months (range 2–180). CONCLUSION: Fertility-sparing treatment of EAC and EIN is a feasible approach, and the eligible patients should be given a chance to get pregnant. The Scientific and Technological Research Council of Turkey 2021-08-30 /pmc/articles/PMC8569776/ /pubmed/34013707 http://dx.doi.org/10.3906/sag-2012-207 Text en Copyright © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Article
İŞÇİ BOSTANCI, Esra
DURMUŞ, Yasin
DURU ÇÖTELİ, A.Sinem
KAYIKÇIOĞLU, Fulya
BORAN, Nurettin
Outcomes of the conservative management of the patients with endometrial intraepithelial neoplasia/endometrial cancer: Wait or treat!
title Outcomes of the conservative management of the patients with endometrial intraepithelial neoplasia/endometrial cancer: Wait or treat!
title_full Outcomes of the conservative management of the patients with endometrial intraepithelial neoplasia/endometrial cancer: Wait or treat!
title_fullStr Outcomes of the conservative management of the patients with endometrial intraepithelial neoplasia/endometrial cancer: Wait or treat!
title_full_unstemmed Outcomes of the conservative management of the patients with endometrial intraepithelial neoplasia/endometrial cancer: Wait or treat!
title_short Outcomes of the conservative management of the patients with endometrial intraepithelial neoplasia/endometrial cancer: Wait or treat!
title_sort outcomes of the conservative management of the patients with endometrial intraepithelial neoplasia/endometrial cancer: wait or treat!
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569776/
https://www.ncbi.nlm.nih.gov/pubmed/34013707
http://dx.doi.org/10.3906/sag-2012-207
work_keys_str_mv AT iscibostanciesra outcomesoftheconservativemanagementofthepatientswithendometrialintraepithelialneoplasiaendometrialcancerwaitortreat
AT durmusyasin outcomesoftheconservativemanagementofthepatientswithendometrialintraepithelialneoplasiaendometrialcancerwaitortreat
AT durucoteliasinem outcomesoftheconservativemanagementofthepatientswithendometrialintraepithelialneoplasiaendometrialcancerwaitortreat
AT kayikcioglufulya outcomesoftheconservativemanagementofthepatientswithendometrialintraepithelialneoplasiaendometrialcancerwaitortreat
AT borannurettin outcomesoftheconservativemanagementofthepatientswithendometrialintraepithelialneoplasiaendometrialcancerwaitortreat